<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03832114</url>
  </required_header>
  <id_info>
    <org_study_id>CLNP023X2202</org_study_id>
    <nct_id>NCT03832114</nct_id>
  </id_info>
  <brief_title>Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted</brief_title>
  <official_title>An Open-label, Non-randomized Study on Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LNP023 in Two Patient Populations With C3 Glomerulopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety,&#xD;
      and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have&#xD;
      undergone kidney transplant and have C3G recurrence (Cohort B).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Actual">April 23, 2021</completion_date>
  <primary_completion_date type="Actual">April 23, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence (Cohort B).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort A: Change from baseline in Urine Protein to Creatinine concentration Ratio (UPCR)</measure>
    <time_frame>Week 12</time_frame>
    <description>Change in proteinuria assessed by ratio to baseline of UPCR derived from 24h urine collection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort B: Change from baseline in C3 Deposit</measure>
    <time_frame>Week 12</time_frame>
    <description>Histopathological changes in kidney biopsies as assessed by change from baseline in C3 Deposit Score (based on immunofluorescence microscopy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in UPCR and Urine Albumine to Creatinine concentration Ratio (UACR)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Ratio to baseline of UPCR and UACR derived from 24h urine collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Urine Protein (UP) and Urine Albumin (UA) concentration</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change and evolution of UA and UP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of LNP023 on renal function - serum creatinine</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change and evolution of serum creatinine and creatinine clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of LNP023 on renal function - estimated glomerular filtration rate</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change and evolution of eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of LNP023 on renal function - hematuria</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change and evolution of hematuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LNP023 Area under the Plasma-concentration-time curve (AUC)</measure>
    <time_frame>Week 1, 2, 3, 4, 13, 14</time_frame>
    <description>Plasma: Non-compartmental parameter analysis related to total drug, including but not limited to AUClast, AUCtau after the first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum concentration after drug administration</measure>
    <time_frame>Week 1, 2, 3, 4, 13, 14</time_frame>
    <description>Plasma: Non-compartmental parameter analysis related to total drug, including but not limited to Cmax after the first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed mimum concentration after drug administration</measure>
    <time_frame>Week 1, 2, 3, 4, 13, 14</time_frame>
    <description>Plasma: Non-compartmental parameter analysis related to total drug, including but not limited to Ctrough (Cmin) after the first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum plasma concentration (Tmax)</measure>
    <time_frame>Week 1, 2, 3, 4, 13, 14</time_frame>
    <description>Plasma: Non-compartmental parameter analysis related to total drug, including but not limited to Tmax after the first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LNP023 in urine</measure>
    <time_frame>Week 1, 2, 3, 4, 13, 14</time_frame>
    <description>Non-compartmental parameters, including but not limited to total cumulative urinary excretion and renal plasma clearance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker C3</measure>
    <time_frame>Week 1,2, 3, 4, and 12</time_frame>
    <description>To assess the effect of LNP023 on alternative complement pathway hyperactivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Bb</measure>
    <time_frame>Week 1, 2, 3, 4 and 12</time_frame>
    <description>To assess the relationship between LNP023 dose and pharmacodynamic biomarker Bb</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Glomerulonephritis</condition>
  <arm_group>
    <arm_group_label>Cohort A - no kidney transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C3G patients who have not received a kidney transplant and have reduced C3 blood levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B - kidney transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C3G patients who have received a kidney transplant and have C3G recurrence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNP023</intervention_name>
    <description>Increasing doses of LNP023 up to 200 mg.</description>
    <arm_group_label>Cohort A - no kidney transplant</arm_group_label>
    <arm_group_label>Cohort B - kidney transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Cohort A and B:&#xD;
&#xD;
          -  Written informed consent must be obtained before any assessment is performed&#xD;
&#xD;
          -  Male and female patients between the ages of 18 to 65 (inclusive) at screening&#xD;
&#xD;
          -  C3G patients wit proteinuria&#xD;
&#xD;
          -  Able to communicate well with the investigator, to understand and comply with the&#xD;
             requirements of the study&#xD;
&#xD;
          -  At screening and baseline visits, patients must weigh at least 35 kg&#xD;
&#xD;
          -  Supine vital signs should be within the following ranges :&#xD;
&#xD;
        oral body temperature between 35.0-37.5 °C systolic blood pressure, 80-170 mm Hg diastolic&#xD;
        blood pressure, 50-105 mm Hg pulse rate, 45 - 100 bpm&#xD;
&#xD;
        .&#xD;
&#xD;
        Inclusion Criteria for Cohort A:&#xD;
&#xD;
          -  Estimated GFR (using the CKD-EPI formula) or measured GFR ≥30 mL/min per 1.73 m2 for&#xD;
             patients on a maximum recommended or maximum tolerated dose of an angiotensin&#xD;
             converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)&#xD;
&#xD;
          -  UPCR ≥ 100 mg/mmol (equivalent to ≥ 1 g/24h total urinary protein excretion)&#xD;
&#xD;
          -  Prior to entry, all patients must have been on supportive care including a maximally&#xD;
             tolerated dose of ACEi or ARB for at least 30 days.&#xD;
&#xD;
        Inclusion Criteria for Cohort B:&#xD;
&#xD;
          -  No histological/laboratory/clinical signs of allorejection&#xD;
&#xD;
          -  If applicable, induction treatment after allotransplantation needs to be completed &gt;30&#xD;
             days before inclusion.&#xD;
&#xD;
          -  Transplantation of a kidney allograft &gt;90 days before inclusion&#xD;
&#xD;
          -  Patients need to be on a stable dose of immunsuppressive regimen prior to inclusion.&#xD;
             Any approved treatments are allowed for this purpose.&#xD;
&#xD;
        Exclusion Criteria for Cohort A and B:&#xD;
&#xD;
          -  Use of other investigational drugs at the time of enrollment, or within 5 half-lives&#xD;
             of randomization, or within 30 days, whichever is longer; or longer if required by&#xD;
             local regulations&#xD;
&#xD;
          -  A history of clinically significant ECG abnormalities,&#xD;
&#xD;
          -  Known family history or known presence of long QT syndrome or Torsades de Pointes&#xD;
&#xD;
          -  Use of agents known to prolong the QT interval unless they can be permanently&#xD;
             discontinued for the duration of the study&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive hCG laboratory test.&#xD;
&#xD;
          -  Women of child bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using highly effective methods of contraception&#xD;
             during dosing and for 1 week after stopping of investigational drug.&#xD;
&#xD;
          -  History of immunodeficiency diseases, or a positive HIV (ELISA and Western blot) test&#xD;
             result.&#xD;
&#xD;
          -  Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV).&#xD;
&#xD;
          -  Patients who cannot receive vaccinations against N. meningitidis, S. pneumoniae, or H.&#xD;
             influenzae&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ranica</city>
        <state>BG</state>
        <zip>24020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

